Targeted NGS Identifies 'Potentially Treatable' Alterations in 90 Percent of Residual Breast Cancers | GenomeWeb

Using targeted next-gen sequencing, a team led by researchers from Vanderbilt University has identified targetable molecular lesions in 90 percent of chemotherapy-resistant triple-negative breast cancers, but they caution the results don't mean most patients will see immediate benefits from such testing going forward.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.